On the other hand, Dono et al. showed excellent overall sensitivity and specificity of MTAP IHC test results as a surrogate of CDKN2A homozygous deletion presence (92.3% and 97.5%, respectively) in meningiomas and IDH-mutant astrocytomas [16]. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).